CRISPR Insider Patel Files Form 4 on Ownership Change

TL;DR

**CRSP insider Patel filed a Form 4, signaling a change in their stock ownership.**

AI Summary

Naimish Patel, an insider at CRISPR Therapeutics AG (CRSP), filed a Form 4 on March 24, 2026, indicating a change in beneficial ownership of securities. While the filing itself doesn't detail specific transactions, it signals that an important executive's holdings have been updated. This matters to investors because changes in insider ownership can sometimes signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.

Why It Matters

This filing updates the public record of an insider's holdings, which can be a subtle indicator of their view on the company's future performance.

Risk Assessment

Risk Level: low — A Form 4 filing itself is a routine disclosure and doesn't inherently indicate high risk without transaction details.

Analyst Insight

Smart investors would monitor subsequent filings or news for specific transaction details (e.g., buys or sells) by Naimish Patel, as this initial Form 4 only indicates a change in ownership without specifying the nature of the change.

Key Players & Entities

• Patel Naimish (person) — Reporting Person, an insider at CRISPR Therapeutics AG
• CRISPR Therapeutics AG (company) — Issuer of the securities
• 0002021679 (person) — CIK for Patel Naimish
• 0001674416 (company) — CIK for CRISPR Therapeutics AG

FAQ

Filing Documents

• ownership.html (4)
• ownership.xml (4) — 7KB
• 0001193125-26-122267.txt ( ) — 8KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Patel Naimish (Last) (First) (Middle) C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET (Street) BOSTON MASSACHUSETTS 02127 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 46.24 03/20/2026 A (1) 38,499 (2) 03/20/2036 Common Shares 38,499 $ 0.00 38,499 D Restricted Stock Units (3) 03/20/2026 A (1) 30,000 (4) (4) Common Shares 30,000 $ 0.00 30,000 D Explanation of Responses: 1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. 2. This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. 3. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. 4. This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. Elizabeth Ryland Waldinger, attorney-in-fact 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR